This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
5 Biotech Stocks in Focus as Race for Coronavirus Vaccine Heats Up
by Ritujay Ghosh
Drugmakers and biotech companies are initiating development of drugs, vaccines and therapies for COVID-19 and substantial progress has been made over the past month.
Major Indexes Defying "Sell in May" Adage: 5 Growth Picks
by Nalak Das
Half of this month is already over, yet Wall Street is in green defying the well-known financial-world adage "Sell in May and go away."
Here's Why Moderna (MRNA) Stock is Jumping Today
by Madeleine Johnson
On Monday, shares of biotech Moderna Inc. (MRNA) soared over 26% in midday trading, and closed up XX% to $X.
Buy Nvidia & Alibaba Stock Before Earnings for Coronavirus Resilience?
by Benjamin Rains
We dive into Nvidia and Alibaba ahead of their quarterly earnings results that are due out this week to help investors decide if either stock might worth buying...
Moderna Soars: Biotech ETFs in Focus
by Neena Mishra
Positive data on early-stage coronavirus vaccine trial sent Moderna shares surging.
Market Gains on Powell's Speech and Moderna's Vaccine
by Zacks Equity Research
Market Gains on Powell's Speech and Moderna's Vaccine.
Moderna (MRNA) COVID-19 Vaccine Looks Promising
by Mark Vickery
This news comes sooner and more positive than analysts had been expecting, and shares are up 35% in early trading this Monday.
Is the Options Market Predicting a Spike in Moderna (MRNA) Stock?
by Zacks Equity Research
Investors need to pay close attention to Moderna (MRNA) stock based on the movements in the options market lately.
Traders Focus on Powell's Comments
by Jeremy Mullin
Futures are flying high before the bell.
Stocks Take a Breather, but Good Weekend News Promises a Boost
by David Borun
Positive comments from the Fed Chairman and promising vaccine trial results provide a chance for a meaningful rally.
Healthcare Tech & Robotics ETFs in Focus amid COVID-19 Crisis
by Neena Mishra
The pandemic will forever transform our lives; here are some areas that may benefit.
The Zacks Analyst Blog Highlights: NVIDIA, Moderna, Clorox, Campbell Soup and General Mills
by Zacks Equity Research
The Zacks Analyst Blog Highlights: NVIDIA, Moderna, Clorox, Campbell Soup and General Mills
Rebalance Your Portfolio to Counter Dilemma Over Recovery
by Nalak Das
At this stage, a combination of aggressive and defensive stocks after filtering with proper selection criteria will be prudent for one's portfolio.
Novovax (NVAX) Surges on CEPI Funding for Coronavirus Vaccine
by Zacks Equity Research
Novovax (NVAX) is set to receive funding of up to $388 million from CEPI to support clinical development and scaling up of production of its coronavirus vaccine candidate.
Biotech Companies Lead Search for Coronavirus Vaccine: 4 Winners
by Zacks.com
Although a vaccine is yet to be developed, many companies have already started ramping up manufacturing process of the experimental vaccine candidates they are working on.
The Zacks Analyst Blog Highlights: Wayfair, Chegg, Moderna, Quidel and Clorox
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Wayfair, Chegg, Moderna, Quidel and Clorox
Novavax Soars on Coronavirus Vaccine Funding: ETFs to Gain
by Sweta Jaiswal, FRM
Novavax received funding for the coronavirus vaccine and also delivered better-than-expected Q1 results resulting in a stock rally in yesterday's trading session.
6 Leveraged ETFs Up At Least 25% Last Week
by Sanghamitra Saha
Oil, tech and biotech caused a rally in the leveraged ETF space last week.
An Outstanding Week for Market Amid Record Job Losses: 5 Picks
by Nalak Das
Market's worst is behind us as negative estimates are already factored in valuations.
6 ETF Areas Beating S&P 500 in 2020
by Sanghamitra Saha
The S&P 500 is down 10.8% this year, after a massive recovery in April. But these ETF areas have beaten the S&P 500 this year.
Moderna (MRNA) Q1 Loss Narrows, Revenues Miss Estimates
by Zacks Equity Research
Moderna (MRNA) reports narrower-than-expected first-quarter loss. The company plans to initiate phase II study on coronavirus vaccine soon.
The Zacks Analyst Blog Highlights: Gilead Sciences, Pfizer, Regeneron Pharmaceuticals, Moderna and Sanofi
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Gilead Sciences, Pfizer, Regeneron Pharmaceuticals, Moderna and Sanofi
Moderna (MRNA) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Moderna (MRNA) delivered earnings and revenue surprises of 5.41% and -53.83%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Biotech ETFs Poised to Benefit From Coronavirus
by Neena Mishra
Rising investor interest in coronavirus related stocks will benefit these ETFs
5 Stocks to Buy as Coronavirus Vaccine in Human Trails Ramp Up
by Zacks Equity Research
As drug makers race to develop vaccine to fight coronavirus, we shortlist five stocks that are poised to grow on progress in clinical trials.